Xavier Rovira, director of the research line in Molecular Photopharmacology in the TR2Lab, has participated in a study which has been awarded the Preclinical Research Award from “Cátedra Extraordinaria del Dolor” of the University of Salamanca – Grünenthal Foundation. This is the second consecutive year a work of Xavier Rovira receives the price in this category. This prize awards a research with animal models, published in the journal eLife, that reached its highest point with the design of the first photoactive drug –JF-NP-26, activated by light─, with potential therapeutic applications to treat pain. The awarded study –co-led by the experts Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona (UB) and Amadeu Llebaria, from the Medicinal Chemistry and Synthesis group (MCS) from the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC)─ is a distinguished progress in the field of photopharmacology, an emerging discipline based on the use of light to control drug activity.

The photoactive drug JF-NP-26 is called a photocaged –a chemically masked and inactive molecule, which is activated by light-, and does not show toxic or unwanted effects on animals, not even with high doses in short-length studies. When given to an animal, it does not have any pharmacologic effect until the target tissue is covered by the light of the visible spectrum (405 nm wavelength).

In the category of Clinical Research, a study led by Professor Enrique Lluch, from the University of Valencia, was also awarded. The study creates pain frequency maps in patients with knee osteoarthritis.

The awards of this chair distinguish the most innovative projects on pain –ranging from epidemiology, experimental, pharmacological and clinical fields-, and were given in an academic ceremony held in the University of Salamanca on January 27.